Jahan Marcu, Ph.D., has over 15 years of experience in academic research, industry, and government relations. Dr. Marcu is presently the Chief Operations Officer, Director of Experimental Pharmacology and Behavioral Research at International Research Center on Cannabis and Mental Health (IRCCMH), which he co-founded. Dr. Marcu is the former Chief Science Officer at Americans for Safe Access (a medical cannabis advocacy non-profit) and former Director of their Patient Focused Certification program, which is a health and safety oversight program that assesses regulatory compliance at cannabis operations. Dr. Marcu published the first direct measurements of THC and CBD synergy, for which he received the Billy Martin research award from the International Cannabinoid Research Society. His Ph.D. focused on solving the structure and function of the CB1 receptor as well as investigating the role of the endocannabinoid system in bone. He has also developed pharmacogenomics testing technology, used commercially and in research studies to predict drug-drug interactions with cannabis, as well as using the technology to guide dosing and administration forms for patients.
Kratom is an unique medicinal herb with pain relieving properties that function as an opiate substitute. So why is the FDA and the DEA trying to block people’s access to it by making it a Schedule 1 drug?
Project CBD science advisor Jahan Marcu, PhD, reports on the hidden dangers of propylene glycol and vape pens that smolder.
Cannabis and its derivatives have been documented for anti-epileptic effects since 1881. Today, the promise of cannabidiol (CBD) as an anti-epileptic treatment is prompting people to move to states that have safe access to medicinal products containing this compound.
Cathy Jordan first noticed something was wrong in 1985 when she couldn’t pick things up. Her muscles weren’t responding. In 1986, she was diagnosed with ALS. Nearly 20 years later she is still alive thanks to cannabis.